28 completed, 5 recruiting, 3 withdrawn, 2 terminated. 18 Phase 2, 10 Phase 3, 9 Phase 1, 5 Phase 4, 1 Early Phase 1.
Follow testosterone enanthate: new trials by email Literature Review of testosterone enanthate trials Research Report on testosterone enanthate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate - Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes | Not applicable | Enrolling by invitation | Enhanced Emirates Limited | 60 | 2026-03-12 | 2026-05-06 |
| 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism Testosterone enanthate - Hypogonadism, Male | Phase 3 | Recruiting | Halozyme Therapeutics | 100 | 2025-03-07 | 2026-02-18 |
| Working Out M0 Bipolar Androgen Therapy Testosterone Enanthate - Prostate Cancer | Phase 2 | Recruiting | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 69 | 2024-08-14 | 2026-04-24 |
| Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD Testosterone Enanthate, Placebo - COPD | Phase 2 / Phase 3 | Withdrawn | The University of Texas Medical Branch, Galveston | 2021-12-01 | 2022-02-02 | |
| Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury Testosterone Enanthate, Locomotor Training - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 | Recruiting | North Florida Foundation for Research and Education | 21 | 2021-01-31 | 2025-05-06 |
| Testosterone Effects on Pelvic Floor Muscles Testosterone Enanthate, Placebo - Urinary Incontinence, Menopause | Phase 3 | Withdrawn | Brigham and Women's Hospital | 2021-01-01 | 2022-07-20 | |
| Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression Testosterone cypionate, Enzalutamide, Testosterone enanthate - Castration Resistant Metastatic Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 150 | 2020-08-19 | 2026-07-17 |
| Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment - Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Completed | University of Washington | 36 | 2018-08-29 | 2025-09-29 |
| Bipolar Androgen Therapy + Carboplatin in mCRPC Testosterone Enanthate 100 MG/ML Injectable Solution, Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5 - Castration-resistant Prostate Cancer, Homologous Recombination Deficiency | Phase 2 | Recruiting | St Vincent's Hospital, Sydney | 30 | 2018-07-30 | 2026-04-23 |
| Study of Testosterone and rHGH in FSHD Testosterone Enanthate, Somatropin - Facioscapulohumeral Muscular Dystrophy | Phase 1 | Completed | University of Rochester | 20 | 2017-12-18 | 2023-05-16 |
| Testosterone Plus Finasteride Treatment After Spinal Cord Injury Testosterone Enanthate, Finasteride, Placebo injection - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 | Terminated | VA Office of Research and Development | 33 | 2017-04-27 | 2023-09-29 |
| Muscle Anabolic Interventions to Accelerate Recovery From Hospitalization in Geriatric Patients Testosterone, Protein Supplement, Placebo Injection - Aging | Phase 1 | Completed | The University of Texas Medical Branch, Galveston | 80 | 2016-09-01 | 2024-12-17 |
| Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism Testosterone enanthate auto-injector - Hypogonadism | Phase 2 | Completed | Antares Pharma Inc. | 66 | 2016-06-01 | 2018-03-22 |
| Physiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery Sesame Oil, testosterone enanthate - Caloric Restriction, Exercise | Phase 4 | Completed | Pennington Biomedical Research Center | 53 | 2016-04-01 | 2019-01-16 |
| Cycled Testosterone Therapy to Improve Physical Function in Frail Nursing Home Residents Placebo, Testosterone - Aging | Early Phase 1 | Terminated | The University of Texas Medical Branch, Galveston | 3 | 2016-02-16 | 2019-02-18 |
| The Effects of Long Term Cyclic Testosterone Administration on Muscle Function and Bone in Older Men Testosterone enanthate, Placebo - Sarcopenia | Phase 4 | Withdrawn | The University of Texas Medical Branch, Galveston | 2016-01-01 | 2015-10-02 | |
| Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism Testosterone enanthate auto-injector - Hypogonadism | Phase 3 | Completed | Antares Pharma Inc. | 133 | 2015-07-01 | 2018-03-30 |
| Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance Testosterone cypionate, Enzalutamide, Testosterone Enanthate - Castration Resistant Metastatic Prostate Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 222 | 2015-01-01 | 2020-11-06 |
| RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) Testosterone cypionate, Testosterone Enanthate, Abiraterone acetate - Prostate Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 112 | 2014-08-25 | 2022-06-27 |
| Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism Testosterone enanthate auto-injector - Hypogonadism | Phase 3 | Completed | Antares Pharma Inc. | 150 | 2014-07-01 | 2018-02-07 |
Showing 20 of 40. Sign in to see all of them.
Hypogonadism (12) · Eunuchism (4) · Motor Activity (3) · Sarcopenia (3) · Wounds and Injuries (3) · Bone Resorption (2) · Cachexia (2) · Central Nervous System Diseases (2) · Endocrine System Diseases (2) · Genital Diseases, Male (2) · Gonadal Disorders (2) · Mobility Limitation (2) · Muscular Atrophy (2) · Nervous System Diseases (2) · Prostatic Neoplasms (2)
The University of Texas Medical Branch, Galveston (8) · Antares Pharma Inc. (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Brigham and Women's Hospital (2) · Clarus Therapeutics, Inc. (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · University of Washington (2) · VA Office of Research and Development (2) · Australian and New Zealand Urogenital and Prostate Cancer Trials Group (1) · Enhanced Emirates Limited (1) · GlaxoSmithKline (1) · Gulhane School of Medicine (1) · Halozyme Therapeutics (1) · Leonard S. Marks, M.D. (1) · M.D. Anderson Cancer Center (1)
United States (34) · Australia (2) · Turkey (Türkiye) (1) · United Arab Emirates (1)
Shalender Bhasin, MD (4) · Samuel Denmeade, MD (3) · Elena Volpi, MD, PhD (2) · Gary Bedel, MD (2) · Jed Kaminetsky, MD (2) · Randall J Urban, M.D. (2) · Anthony Joshua (1) · Anthony M Joshua, MBBS, PhD, FRACP (1) · Aydogan Aydogdu, MD (1) · Chad R Heatwole, MD, MS-CI (1) · Dana M Otzel, PhD (1) · Dana M Otzel, Phd (1) · Edgar L Dillon, PhD (1) · Grace Huang, MD (1)
PMID 17105798, PMID 18046048, PMID 18430965, PMID 21474786, PMID 22396515, PMID 24012740, PMID 24326421, PMID 25481088, PMID 28479217, PMID 28591764, PMID 28840147, PMID 29188864, PMID 29248236, PMID 29280355, PMID 29532075, PMID 30906944, PMID 30932132, PMID 31391011, PMID 31551193, PMID 31894236, PMID 32203306, PMID 32258956, PMID 32624280, PMID 33383350, PMID 33417663, PMID 33617303, PMID 35532889, PMID 36481265, PMID 36563086, PMID 37251511, PMID 39722695, PMID 40900971, PMID 41316872, PMID 41724634
I01RX001449 (1), K23HD045386 (1), P30CA015704 (1), R01AG022023 (1), R01AG037547 (1), R01CA127971 (1), R01CA184012 (1), R01DK049296 (1), R01HD043348 (1), U54HD042454 (1)